Xen® Gel Stent versus PreserFlo™ MicroShunt as a subconjunctival shunt devices in glaucoma: a systematic review
DOI:
https://doi.org/10.13181/mji.oa.258110Keywords:
filtering surgery, glaucoma, glaucoma drainage implants, intraocular pressure, minimally invasive surgical proceduresAbstract
BACKGROUND Glaucoma is the leading cause of irreversible blindness and is primarily managed by reducing intraocular pressure (IOP). Minimally invasive glaucoma surgeries, particularly subconjunctival shunt devices such as Xen® Gel Stent and PreserFlo™ MicroShunt, have emerged as alternatives to traditional trabeculectomy. This study aimed to evaluate their effectiveness in lowering IOP, reducing medication use, and assessing reinterventions and safety.
METHODS A systematic review was conducted in accordance with Cochrane and PRISMA guidelines. Comprehensive literature searches were conducted across PubMed, Cochrane, EBSCOhost, and Google Scholar databases from the earliest available date to September 2023. Studies comparing Xen® Gel Stent and PreserFlo™ MicroShunt in adult patients with glaucoma were included. Data were extracted on study design, sample size, IOP outcomes, antiglaucoma medication use, reinterventions, and safety outcomes. Quality assessment was performed using the Newcastle-Ottawa Scale.
RESULTS Of 5 European studies (2020–2023; 329 patients, 6–18 months of follow-up), 3 studies reported lower postoperative IOP with PreserFlo™ MicroShunt (11.8 [3.7] versus 13.6 [3.5] mmHg, p = 0.02; 10.3 [2.1] versus 14.2 [2.1] mmHg, p = 0.0005; 10.3 [3.2] versus 13.1 [6.4] mmHg, p = 0.019). Only one study noted fewer antiglaucoma medications with PreserFlo™ MicroShunt (0.2 [0.6] versus 1.1 [2.4], p = 0.04). Reinterventions including needling and bleb revisions were higher with Xen® Gel Stent (35.4% versus 11.5%; 20% versus 5%). Complication profiles varied, with hypotony more common in Xen® Gel Stent (6.5% versus 0%), hyphema more common with PreserFlo™ MicroShunt (7.7% versus 3.2%), and stent curling and migration more common with Xen® Gel Stent (15% versus 0%; 2% versus 0%), respectively.
CONCLUSIONS Both Xen® Gel Stent and PreserFlo™ MicroShunt effectively lowered IOP and reduced medication burden in patients with glaucoma. PreserFlo™ MicroShunt may provide superior IOP control and fewer postoperative interventions. Further prospective studies in diverse populations are warranted.
Downloads
References
Allison K, Patel D, Alabi O. Epidemiology of glaucoma: the past, present, and predictions for the future. Cureus. 2020;12(11):e11686. https://doi.org/10.7759/cureus.11686
Rif'Ati L, Halim A, Lestari YD, Moeloek NF, Limburg H. Blindness and visual impairment situation in Indonesia based on rapid assessment of avoidable blindness surveys in 15 provinces. Ophthalmic Epidemiol. 2021;28(5):408-19. https://doi.org/10.1080/09286586.2020.1853178
Goel M, Picciani RG, Lee RK, Bhattacharya SK. Aqueous humor dynamics: a review. Ophthalmol J. 2010;4:52-9. https://doi.org/10.2174/1874364101004010052
Sihota R, Angmo D, Ramaswamy D, Dada T. Simplifying "target" intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma. Indian J Ophthalmol. 2018;66(4):495-505. https://doi.org/10.4103/ijo.IJO_1130_17
Cairns JE. Trabeculectomy. Preliminary report of a new method. Am J Ophthalmol. 1968;66(4):673-9. https://doi.org/10.1016/0002-9394(68)91288-9
Agrawal P, Bradshaw SE. Systematic literature review of clinical and economic outcomes of micro-invasive glaucoma surgery (MIGS) in primary open-angle glaucoma. Ophthalmol Ther. 2018;7(1):49-73. https://doi.org/10.1007/s40123-018-0131-0
Hasan SM, Theilig T, Papadimitriou M, Meller D. A comparative analysis of morphology and dimensions of functional blebs following PRESERFLO-Microshunt and XEN-Gel-Stent, a study using anterior segment OCT. Diagnostics (Basel). 2023;13(14):2318. https://doi.org/10.3390/diagnostics13142318
Scheres LM, Kujovic‐Aleksov S, Ramdas WD, De Crom RM, Roelofs LC, Berendschot TT, et al. XEN® Gel Stent compared to PRESERFLOTM MicroShunt implantation for primary open-angle glaucoma: two-year results. Acta Ophthalmol. 2021;99(3):e433-40. https://doi.org/10.1111/aos.14602
Gambini G, Carlà MM, Giannuzzi F, Boselli F, Grieco G, Caporossi T, et al. Anterior segment-optical coherence tomography bleb morphology comparison in minimally invasive glaucoma surgery: XEN Gel Stent vs. PreserFlo MicroShunt. Diagnostics (Basel). 2022;12(5):1250. https://doi.org/10.3390/diagnostics12051250
Giansanti F, Quaranta G, Serino F, Vicini G, Franco F. Comparison of clinical outcomes between XEN gel stent and PreserFlo microshunt: a monocentric experience. J Clin Exp Ophthalmol. 2023;14(4):953.
Theilig T, Papadimitriou M, Albaba G, Meller D, Hasan SM. Results of open bleb revision as management of primary bleb failure following XEN 45 gel stent and PreserfloTM Microshunt. Graefes Arch Clin Exp Ophthalmol. 2023;261(11):3249-55. https://doi.org/10.1007/s00417-023-06152-8
Panarelli JF, Yan DB, Francis B, Craven ER. XEN gel stent open conjunctiva technique: a practical approach paper. Adv Ther. 2020;37(5):2538-49. https://doi.org/10.1007/s12325-020-01278-1
Fea AM, Durr GM, Marolo P, Malinverni L, Economou MA, Ahmed I. XEN® Gel Stent: a comprehensive review on its use as a treatment option for refractory glaucoma. Clin Ophthalmol. 2020;14:1805-32. https://doi.org/10.2147/OPTH.S178348
Saeed E, Gołaszewska K, Dmuchowska DA, Zalewska R, Konopińska J. The PreserFlo MicroShunt in the context of minimally invasive glaucoma surgery: a narrative review. Int J Environ Res Public Health. 2023;20(4):2904. https://doi.org/10.3390/ijerph20042904
Lenzhofer M, Strohmaier C, Sperl P, Hohensinn M, Hitzl W, Steiner V, et al. Effect of the outer stent position on efficacy after minimally invasive transscleral glaucoma gel stent implantation. Acta Ophthalmol. 2019;97(8):e1105-11. https://doi.org/10.1111/aos.14167
De Gregorio A, Pedrotti E, Stevan G, Bertoncello A, Morselli S. XEN glaucoma treatment system in the management of refractory glaucomas: a short review on trial data and potential role in clinical practice. Clin Ophthalmol. 2018;12:773-82. https://doi.org/10.2147/OPTH.S146919
Teus MA, Paz Moreno-Arrones J, Castaño B, Castejon MA, Bolivar G. Optical coherence tomography analysis of filtering blebs after long-term, functioning trabeculectomy and XEN® stent implant. Graefes Arch Clin Exp Ophthalmol. 2019;257(5):1005-11. https://doi.org/10.1007/s00417-019-04272-8
Midha N, Rao HL, Mermoud A, Mansouri K. Identifying the predictors of needling after XEN gel implant. Eye (Lond). 2019;33(3):353-7. https://doi.org/10.1038/s41433-018-0206-0
Galimi ME, Weller JM, Kruse FE, Laemmer R. Risk factors for ocular hypotony after XEN Gel Stent implantation. Graefes Arch Clin Exp Ophthalmol. 2023;261(3):769-78. https://doi.org/10.1007/s00417-022-05831-2
Rezkallah A, Mathis T, Denis P, Kodjikian L. XEN gel stent: a total delayed-onset postoperative hyphema. Int J Ophthalmol. 2019;12(7):1224-6. https://doi.org/10.18240/ijo.2019.07.27
Cutolo CA, Negri L, Olivari S, Cappelli F, Traverso CE, Iester M. Choroidal detachment after XEN Gel Stent implantation. J Ophthalmol. 2021;2021:6674505. https://doi.org/10.1155/2021/6674505
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Muhammad Khoirul Huda, Astrianda Nadya Suryono
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.
